Skip to content

Clinical trials

Amyloidosis trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Amyloidosis Country / region: United States Clear all

133 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20032
20053
20062
20071
20083
20093
20102
20113
20123
20139
20144
20155
20169
20176
20187
201911
20206
202112
20225
20238
20247
202510
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed66
Recruiting30
Terminated14
Active, not recruiting7
Withdrawn5
Unknown status5
Enrolling by invitation3
Not yet recruiting2
No longer available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Alnylam Pharmaceuticals13
Mayo Clinic9
Brigham and Women's Hospital7
Ionis Pharmaceuticals, Inc.7
Pfizer7
Eidos Therapeutics, a BridgeBio company5
The Cleveland Clinic4
University of Texas Southwestern Medical Center4
Boston University3
Janssen Research & Development, LLC3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Amyloidosis133
Amyloid Neuropathies, Familial29
Immunoglobulin Light-chain Amyloidosis25
Cardiomyopathies21
Alzheimer Disease18
Multiple Myeloma17
Amyloidosis, Familial12
Polyneuropathies12
Paraproteinemias5
Amyloid Neuropathies4

Trials

Showing 1 to 25 of 133. Each trial links to its page on Pharma Observatory.

33 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.